Amgen Continues to Grow Monoclonal Antibody Arsenal with Kirin’s KHK4083
By Debadrita Paul
Pharma Deals Review: Vol 2021 Issue 6 (Table of Contents)
Published: 25 Jun-2021
DOI: 10.3833/pdr.v2021.i6.2615 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to bolster its inflammatory disease portfolio, Amgen has agreed to partner with Kyowa Kirin to develop and commercialise the latter’s Phase III-ready asset, KHK4083...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS